15/09/2026
Mount Elizabeth Hospitals and Parkway Cancer Centre have expanded its ๐ฐ๐ฒ๐น๐น๐๐น๐ฎ๐ฟ ๐๐ต๐ฒ๐ฟ๐ฎ๐ฝ๐ ๐ฐ๐ฎ๐ฝ๐ฎ๐ฏ๐ถ๐น๐ถ๐๐ถ๐ฒ๐ with the recent administration of FUCASO (equecabtagene autoleucel), an HSA-registered BCMA-directed CAR T-cell therapy, to an eligible patient with relapsed or refractory multiple myeloma.
๐๐๐ฅ ๐ง-๐ฐ๐ฒ๐น๐น ๐๐ต๐ฒ๐ฟ๐ฎ๐ฝ๐ ๐ถ๐ ๐ฎ ๐ฝ๐ฒ๐ฟ๐๐ผ๐ป๐ฎ๐น๐ถ๐๐ฒ๐ฑ ๐๐ฟ๐ฒ๐ฎ๐๐บ๐ฒ๐ป๐ ๐ฎ๐ฝ๐ฝ๐ฟ๐ผ๐ฎ๐ฐ๐ต ๐ถ๐ป ๐๐ต๐ถ๐ฐ๐ต ๐ฎ ๐ฝ๐ฎ๐๐ถ๐ฒ๐ป๐'๐ ๐ผ๐๐ป ๐ง ๐ฐ๐ฒ๐น๐น๐ ๐ฎ๐ฟ๐ฒ ๐ฐ๐ผ๐น๐น๐ฒ๐ฐ๐๐ฒ๐ฑ ๐ฎ๐ป๐ฑ ๐ฟ๐ฒ-๐ฒ๐ป๐ด๐ถ๐ป๐ฒ๐ฒ๐ฟ๐ฒ๐ฑ ๐ถ๐ป ๐ฎ ๐น๐ฎ๐ฏ๐ผ๐ฟ๐ฎ๐๐ผ๐ฟ๐ ๐๐ผ ๐ฟ๐ฒ๐ฐ๐ผ๐ด๐ป๐ถ๐๐ฒ ๐ฎ ๐๐ฝ๐ฒ๐ฐ๐ถ๐ณ๐ถ๐ฐ ๐๐ฎ๐ฟ๐ด๐ฒ๐ ๐ผ๐ป ๐ฐ๐ฎ๐ป๐ฐ๐ฒ๐ฟ ๐ฐ๐ฒ๐น๐น๐. The modified T cells are then infused back into the patient, where they can identify and attack cells carrying that target.
The treatment involved close coordination across specialist assessment, cell collection, manufacturing, infusion and post-treatment monitoring, led by haematologist ๐๐ฟ ๐๐ผ๐น๐ถ๐ป ๐๐ถ๐ผ๐ป๐ด and the multidisciplinary care team at Mount Elizabeth Hospitals and Parkway Cancer Centre.
This development reflects the continued expansion of our capabilities in complex blood cancer care and cellular therapy.
Learn more about ๐ ๐ผ๐๐ป๐ ๐๐น๐ถ๐๐ฎ๐ฏ๐ฒ๐๐ต ๐๐ฎ๐ป๐ฐ๐ฒ๐ฟ ๐๐ฎ๐ฟ๐ฒ: https://www.mountelizabeth.com.sg/cancer-care